Across TCGA pan-cancer cohorts, CDRT15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CDRT15 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CDRT15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDRT15 expression acts as an unfavorable survival marker.

LUAD and PRAD are the cancer types where CDRT15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.079	0.788	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CDRT15 tumor-vs-normal RNA expression · all CDRT15 data types